Pete Salzmann is the founder of Immunovant. Immunovant has raised $450M in total funding. Latest round: Post-IPO. Backed by Roivant. Based in New York, NY.
Pete Salzmann is the Chief Executive Officer of Immunovant, a clinical-stage immunology company focused on developing therapies for autoimmune diseases. Immunovant recently announced a private placement of $450 million to advance its development pipeline and for general corporate purposes.
Full founder directory · Investor directory · Company funding database · Fundraising library